The HypoDE study demonstrated that real-time continuous glucose monitoring (rtCGM) can reduce biochemical as well as clinical hypoglycemia in people with hypoglycemia problems. However, it is not clear how quick a reduction of low glucose values via rtCGM occurs and how sustainable this is. We analyzed the rtCGM group of the HypoDE study and compared the 4-week baseline phase with masked rtCGM to three 4-week intervals within the therapy/outcome phase (T/O phase) with open rtCGM (Dexcom G5). Only participants with no recent experience with CGM were included. At baseline, 6.5±6.2% of the glucose values of the 75 participants were below 70 mg/dl and 2.5±3.3% were below 54 mg/dl. In the first week, these percentages dropped significantly to 2.9±0.4%, respectively 0.7±1.3%. For the remainder of the T/O phase, these percentages stayed stable (not crossing the lower 95% CI interval of the baseline values; see Figure). Time-in-Range (TIR) improved significantly in the first 12 weeks and then started to drop to baseline level. rtCGM results in an immediate and significant reduction of level 1 (< 70 mg/dl) and level 2 (< 54 mg/dl) hypoglycemic values. This initial effect can be sustained throughout the entire study period without wear off. The avoidance of hypoglycemia was not associated with a deterioration of TIR.


D. Ehrmann: Advisory Panel; Self; Medtronic. Speaker's Bureau; Self; Abbott, Berlin-Chemie AG, Dexcom, Inc. L. Heinemann: Consultant; Self; Roche Diabetes Care. Research Support; Self; Dexcom, Inc. Stock/Shareholder; Self; Profil Institute for Metabolic Research, ProSciento. G. Freckmann: Advisory Panel; Self; Abbott, Novo Nordisk Pharma GmbH, Sensile Medical AG. Consultant; Self; Metronom Health Europe, Roche Diabetes Care, Sanofi. Speaker's Bureau; Self; Ascensia Diabetes Care, Dexcom, Inc., Ypsomed AG. D. Waldenmaier: None. N. Hermanns: Advisory Panel; Self; Abbott. Board Member; Self; Eli Lilly and Company. Research Support; Self; Abbott, Berlin-Chemie AG, Dexcom, Inc., Roche Diabetes Care. Speaker's Bureau; Self; Berlin-Chemie AG, Dexcom, Inc., Novo Nordisk A/S.


Dexcom, Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at